Introduction
============

Colorectal cancer (CRC) is a considerable global health problem in the world and the third diagnosed malignancy following lung and breast cancer (Peters et al., 2016; Hale et al., 2017). CRC is one of the major causes of cancer death in western countries and also the third most common cancer in Iran (Ansari et al., 2006; Haghdoost et al., 2011). Most CRC cases progress from precursors recognized as colorectal polyps; the two common types of polyps include: hyperplastic (HP) and adenomatous polyps (AP). AP itself is divided in three main sub-groups of tubular adenoma (TP), tubuvillous (TVP), and villus (VP). Previous investigations (Leslie et al., 2002; Kim et al., 2011) have shown that colorectal tumors may originate from transformed polyps within several years. Histologically, colorectal polyps are found in different shapes including adenoma, hyperplastic, hamartomatous, and inflammatory polyps (Leslie et al., 2002). Neoplastic or adenoma polyps are more important as they are suspected of being malignant and cancerous (O'Connell and Crockett, 2017). Indeed, recent investigations have revealed that hyperplastic polyps have the malignancy potential in some cases (Liljegren et al., 2003; Inoue et al., 2007). The relationship between inflammation and tumor is becoming increasingly important in the study on the pathogenesis of CRC. Several studies have confirmed that TLRs as immune molecules could mediate inflammatory response and play an important role in this process (Chen et al., 2007; Kolumam et al., 2005; Siegel et al., 2016). Nevertheless, the role of *TLR9*-mediated immune inflammation reaction in the process is not currently clear (Caixia et al., 2018). In this study, we dealt with evaluating the expression level of the *TLR9* in colonic AP and HP cases in contrast to healthy subjects and with finding the relationship between *TLR9 mRNA* expression level and pathological features of AP and HP cases.

Materials and Methods
=====================

*Human sample collection*

The present study was case control and the investigated population (54 patients with polyp and 20 normal individuals) was chosen from the cases with colorectal polyps who were referred to Taleghani hospital, Shahid Beheshti University of Medical Sciences, Tehran-Iran, between October 2015 and April 2017. The sample was chosen through ransom sampling. Colorectal polyps were identified through colonoscopy and confirmed by pathology results. Polyp-free controls were defined as those with no polyps identified during colonoscopy and no previous history of colorectal polyps. Polyp type classifications were done according to polyp histology; hyperplasic (HP), tubular adenoma (TA), and tubulovillous polyp (TVP), where dysplasia grades and polyp sizes were characterized by a pathologist. The clinical information of patients was collected by a questionnaire. The study was approved by the Clinical Research Ethics Committee of Shahid Beheshti University of Medical Sciences and the Ethics Committee of Taleghani Hospital, Tehran, Iran with No.2014/770.
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###### 

Oligonucleotides Pair of Primers Used for the Relative Gene Expression

  Gene      Primer Sequence
  --------- -------------------------------
  TLR9-F    5'\_AATCCCTCATATCCCTGTCCC_3'
  TLR9-R    5'\_GTTGCCGTCCATGAATAGGAAG_3'
  GAPDH-F   5'-TGACTTCAACAGCGACACCCA-3'
  GAPDH-R   5'-CACCCTGTTGCTGTAGCCAAA-3'

###### 

Clinicopathological Parameters of Patient with Different Polyps

  Parameter     Type             Number
  ------------- ---------------- ------------
  Polyp types   Hyperplastic     26 (48.3%)
                Tubular          7 (12.9%)
                Tubullovillous   21 (38.8%)
  Dysplasia     HGD              24 (44.5%)
                LGD              30 (55.%)
  Gender        Male             28 (52%)
                Female           26 (48%)
  Site          Rectum           16 (29.6%)
                AC               7 (13%)
                AD               15 (27.8%)
                TC               16 (29.6%)
  Total                          54 (100)

*RNA extraction and quality control*

Total RNA was extracted from all samples (Yekta Tajhiz Azma kit, Teheran, Iran) according to the kit instructions. RNA concentration and purity ratios (OD260/280, OD260/230) were evaluated by NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The integrity of RNA was determined by electrophoresis on a denaturing 1.5% agarose gel.

*cDNA synthesis*

Total RNAs were converted to cDNA by Retrotransciptase (RT) reaction (TaKaRa kit, Cat No.RR037A, Otsu, Shiga, Japan) according to the following: 2 mg of total RNA was picked up and denatured at 95°C for 5 min. Thereafter, the tubes were placed on ice where 5 μL of 5×primer script buffer, 0.5 μL RT enzyme, 1.24 μM oligo dt primer, 10 μM random 6 mer, 1 μM ribolock, 1 μL easy dilution, and 5 μL RNA free distilled water (dH~2~O), were added. The cDNA synthesis was performed as follows: 25°C for 5 min, 42°C for 15 min, 85°C for 1 min for inactivation of the reverse transcriptase enzyme and 4°C for 10 min for hold temperature. Next, cDNA products were stored at -20°C. Note that in all reactions, the same concentrations of RNA samples were used (RNA adjustment).

*Real time-PCR*

Real-time PCR was performed following the standard SYBR Premix Ex Taq™ kit (TaKaRa Bio Inc., Otsu, Japan) protocol, using a final volume of 20 μL containing 5 μL of reverse-transcribed cDNA and 1 μL of 10 pmol forward and reverse primers, using Applied Biosystems 7500 version 1 (ABI, Foster City, CA, USA). Real-time PCR was carried out by expressive primers ([Table 1](#T1){ref-type="table"}) under the following conditions: 95°C for 5 s, 40 cycles of 95°C for 5 s, 60°C for 34 s, 95°C for 15 s, 60°C for 1 s and 60°C for 15s (Khatibi et al., 2018). Amplification signals for samples were normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. Fold change of gene expression was evaluated by 2^-ΔΔct^ method.

*Statistical analysis*

All results were analyzed by Graph pad Prism software version 5 (San Diego, CA, USA). The data were non-normally distributed and the non-parametric test was used. Specifically, student t-test and one-way ANOVA test were performed. *P-value* \< 0.05 was considered statistically significant.

Results
=======

Among 54 polyp cases, 26 (48.3%) were identified as hyperplastic, 7 (12.9 %) as tubular, and 21 (38.8%) as tubulovillous. Clinicopathological parameters of patients with different polyp types are presented in [Table 2](#T2){ref-type="table"}. Based on these results, there was a significant relationship between the lower expression level of *TLR9* in the polyp cases compared with normal samples (*P-value*= 0.0005) ([Figure 1](#F1){ref-type="fig"}). Also, comparing AP (TP, TVP), HP, and control groups, diminished expression level of *TLR9* was obtained in aAP in contrast to HP cases and normal individuals (*P-value* = 0.0008) ([Figure 2](#F2){ref-type="fig"}). Consequently, *TLR9 mRNA* expression was evaluated in both high grade dysplasia (HGD) and low-grade dysplasia (LGD) in contrast to the control group, where lower expression levels were achieved for HGD and LGD (*P-value*= 0.002) ([Figure 3](#F3){ref-type="fig"}). Finally, the level of *TLR9* expression was lower in TP compared with TVP (RQ\<0/05). This indicated significant differentiation between these polyp types (*P-value*= 0.004) ([Figure 4](#F4){ref-type="fig"}).

Discussion
==========

Investigation of the main molecular and immunological events in different types of polyp is important (Baxevanis et al., 2013) especially regarding early diagnosis of CRC and improving the management of patients. In the current study, it was found that TLR-9 mRNA expression was reduced in AP and HP cases compared with the normal individuals; hence, it was suggested that reduction of TLR-9 may play an important role in CRC initiation. Also, these data may support the development of TLR-9 agonists (synthetic oligodeoxynucleotides \[ODNs\]) for cancer treatment. However, the role of *TLR9* in CRC pathology has not been fully elucidated up to now. Interestingly, we observed lower expression levels of *TLR9* in *HGD* and *LGD* compared with normal participants. Also, we found various levels of *TLR9 mRNA* in different polyp types such as TP and TVP types. Our results were in contrast with Yesudhas et al., (2014) indicating that TLR7, 8, 9, and 10 mRNA expression increased in tissues of CRC patients. Indeed, they worked on CRC cases while the present study focused on different polyp cases; hence these differences may arise from differences between polyp and tumor tissues. On the other hand, Sandholm et al., (2014) demonstrated the beneficial role of *TLR9* on breast cancer treatment (Sandholm and Selander, 2014). Also, Shahriari et al., (2017) hypothesized that aberrant surface expression of *TLR9* on tumor cells may promote tumor growth and invasion. They highlighted a dual contradictory role for CpG-ODNs, as an adjuvant agent in cancer therapy. Hasan et al., (2007) as well as Pacini et al., (2015) reported that downregulation of *TLR9* may be a crucial step in the carcinogenic events of human papillomavirus associated with cervical cancer. Furthermore, some researchers declared that oncogenic viruses such as papillomavirus 16, Epstein-Barr virus, and hepatitis B virus may have an important role in downregulating *TLR9* expression (Fathallah et al., 2010; van Gent et al., 2011; Vincent et al. 2011). Finally, Jouhi et al., (2015) findings revealed diminishing expression levels of *TLR9* during Merkel cell carcinoma.

In conclusion, we observed decreasing *TLR*9 expression in polyp cases of patients compared to normal samples. Also, lower expression level of *TLR9* in *HGD*and*LGD* compared to normal participants was achieved and different expression levels were obtained between TP and TVP. According to these results, it can be concluded that the reduction of *TLR9* expression may play a significant role in the progression of polyps to CRC and malignancy. Indeed, cancer cells may be able to escape the immune system due to *TLR9* reduction. Finally,*TLR9* modulation may have an impact on the development of novel therapeutic strategies.
